U
SGMO

UBS’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

UBS’s Portfolio SGMO Stock Details SGMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		$505K Buy
46,800
+40,800
+680% +$533K ﹤0.01% 4271
2014
Q2 		$92K Sell
6,000
-69,800
-92% -$1M ﹤0.01% 6035
2014
Q1 		$1.37M Buy
75,800
+48,800
+181% +$941K ﹤0.01% 3149
2013
Q4 		$375K Sell
27,000
-23,500
-47% -$271K ﹤0.01% 4615
2013
Q3 		$530K Sell
50,500
-107,500
-68% -$1.07M ﹤0.01% 4069
2013
Q2 		$1.23M Buy
+158,000
New +$1.38M ﹤0.01% 3094

Other funds holding SGMO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return

UBS's SGMO Position: Q3 2014 in Review

UBS increased its SANGAMO THERAPEUTICS INC (SGMO) stake by 223% in Q3 2014, buying an estimated $221K and bringing the position to 24,550 shares worth $265K. The position accounts for ﹤0.01% of the portfolio, ranked #4898.

UBS first reported a position in SGMO in Q2 2013 and has held it in 6 quarters since. 157 funds tracked by Wall St. Rank hold SGMO as of Q3 2014.

  • UBS held 24,550 shares of SANGAMO THERAPEUTICS INC worth $265K as of Q3 2014.
  • UBS bought 16,950 SANGAMO THERAPEUTICS INC shares in Q3 2014, an estimated $221K.
  • SANGAMO THERAPEUTICS INC made up ﹤0.01% of UBS's portfolio in Q3 2014, its #4898 holding.
  • UBS first reported a position in SANGAMO THERAPEUTICS INC in Q2 2013 and has held it in 6 quarters since.
  • 157 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q3 2014.

Based on UBS's 13F filing for Q3 2014, filed 12 Nov 2014.